If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Share News (CSRT)

  • There is currently no data for CSRT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Consort Medical First Half Profit Falls Due To Cramlington Incident

Tue, 03rd Dec 2019 09:14

(Alliance News) - Consort Medical PLC on Tuesday said its interim profit was considerably smaller following an incident at its Aesica Cramlington manufacturing facility.

Consort's pretax profit for the six months ended October 31 was GBP1.2 million, far less than the GBP9.6 million profit posted the year before as revenue fell 4.3% to GBP146.0 million from GBP152.5 million.

This was primarily caused by the Cramlington incident, in which a small area of the Northumberland-based operating plant was damaged in what was described by Consort at the time as "the rapid thermal degradation of a chemical resulting in the expulsion of material and contamination of the facility".

This hurt the performance of its active pharmaceutical ingredients and finished dose manufacturing unit, Aesica, where revenue fell 11% to GBP81.1 million from GBP90.9 million.

Bespak, Consort's drug delivery devices unit, was unaffected, with revenue up 5.4% at GBP64.9 million versus GBP61.6 million the year prior.

On November 18, following the end of its first half, contract development and manufacturing pharmaceutical company Consort agreed to a GBP505 million bid from Swedish peer Recipharm AB. Recipharm will pay 1,010 pence in cash for each Consort share. The proposed deal implies an enterprise value of GBP627 million for Consort.

Given that Recipharm may reduce its acquisition consideration if any dividend or other distribution is made by the Hemel Hempstead-based company, Consort has opted not to declare an interim dividend.

Consort Chief Executive Jonathan Glenn said: "The board's expectations for the full year remain unchanged. We anticipate that the group's performance in the second half of the year will benefit from continued growth in Bespak, recommencing manufacture of the specific product involved in the Cramlington incident and a reduction in the backlog at Aesica.

"The group is subject to a recommended offer from Recipharm Holdings Ltd. The board remains confident of Consort's future prospects."

Shares in Consort were down 0.5% at 1,040.00 pence in London on Tuesday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2017 08:10

Consort Medical splutters as BAT stubs out Voke programme

(ShareCast News) - British American Tobacco has terminated an agreement with Consort Medical over the manufacture of nicotine inhalers for its Voke development programme. Consort, which said it was in "constructive dialogue" with BAT's Nicovations arm and product developer Kind Consumer over the fut

Read more
6 Dec 2016 08:18

Consort Medical posts good growth in first half

(ShareCast News) - Single source drug and delivery device company Consort Medical announced its interim results for the six months to 31 October on Tuesday. The London-listed firm said group revenue increased to £144.9m from £135.5m, representing underlying growth of 2.0% and reported growth of 6.9%

Read more
25 Nov 2016 09:07

Consort Medical appoints new CFO

(ShareCast News) - Consort Medical, a global provider of manufacturing solutions for drugs, announced that it has appointed Paul Hayes as group Finance Director of the Vitec Group. Hayes is taking over the position of chief financial officer from Richard Cotton as well joining the board as executive

Read more
27 Oct 2016 07:45

Consort Medical Welcomes Cimzia Autoclicks Launch On NHS

Read more
14 Oct 2016 12:23

Consort Medical's Bespak inks new agreement

(ShareCast News) - Consort medical, a global single source drug and Delivery device company (CDMO), has announced that its Bespak division has entered into an agreement with a biopharmaceutical company. Bespak manufactures drug delivery devices for pharmaceutical partner companies including respirat

Read more
19 Sep 2016 09:07

Consort Notes European Nod For Bespak Technology-Using Product

Read more
7 Sep 2016 08:43

Consort Medical signs agreement with AstraZeneca

(ShareCast News) - Consort medical, a provider of advanced technology for drugs, has signed a new contract with pharmaceutical giant AstraZeneca for the supply of its Bespak respiratory devices. AstraZeneca and Bespak have agreed to enter into a multi-year agreement for the scale-up and supply of Be

Read more
7 Sep 2016 07:03

Consort Medical Sees Little Brexit Impact; Signs Deal With AstraZeneca

Read more
23 Jun 2016 15:19

Director dealings: Derwent London CEO sells just ahead of Brexit vote

(ShareCast News) - Derwent London chief executive John Burns has sold £1.5m of the FTSE 250 real estate investor's shares in the week just before the EU referendum which could seriously lift or undermine the company's shares. In Wednesday's sale, which comes two days before results for Britain's ref

Read more
17 Jun 2016 09:29

Numis places Consort Medical 'under review'

(ShareCast News) - Consort Medical's shares were put 'under review' by Numis after the company reported its full year results. The pharmaceutical device frim on Thursday reported full year earnings before interest and tax rose 47.6% to £37m as revenues gained 49.8% to £276.9m, driven by a strong per

Read more
16 Jun 2016 14:52

Consort Medical's annual revenues rise as a product launch is delayed

(ShareCast News) - Consort Medical, a pharmaceutical device company, revealed higher full year profits on Thursday due to organic growth and an acquisition. Revenues rose 49.8% to £276.9m from £184.8m the previous financial year. Bespak, the company's drug device manufacturing subsidiary, continued

Read more
16 Jun 2016 07:37

Consort Medical Profit Doubles As Progress Made On DEV610 Programme

Read more
9 Jun 2016 15:04

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
5 Apr 2016 08:32

BROKER RATINGS SUMMARY: Liberum Upgrades Babcock To Hold From Sell

Read more
22 Feb 2016 16:51

Consort Medical agrees partnership and invests in Precision Ocular

(ShareCast News) - Consort Medical has made a £3.3m equity investment for a 13.7% stake in retinal therapeutics specialist Precision Ocular and agreed a development and manufacturing partnership. London-based Precision Ocular has developed retinal treatments that are designed to access specific sma

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.